Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus

3 Jun 2021

Abstract excerpt

An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of Coronavirus Disease-2019 (COVID-19), a respiratory disease, has infected almost one hundred million people since the end of 2019, killed over two million, and caused worldwide social and economic disruption. Because the mechanisms of SARS-CoV-2 infection of host cells and its pathogenesis remain largely unclear, there are currently no...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 and healthcare impacts
Share to Dermatological and COVID-19 studies
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34083759
DOI: 10.1038/s42003-021-02220-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virusPMID 34083759Read ↗

SARS-CoV-2 infection as a potential risk factor for the development of cancerSemantic proximity Read ↗

Deciphering the Relationship between SARS-CoV-2 and CancerSemantic proximity Read ↗

The Interference between SARS-CoV-2 and Tyrosine Kinase Receptor Signaling in CancerSemantic proximity Read ↗

SARS‐CoV‐2 infection and cancerSemantic proximity Read ↗

Recent Updates on Viral Oncogenesis: Available Preventive and Therapeutic EntitiesSemantic proximity Read ↗

New Insights into SARS-CoV-2 and Cancer Cross-Talk: Does a Novel Oncogenesis Driver Emerge?Semantic proximity Read ↗

Safeguarding COVID-19 and cancer management: drug design and therapeutic approachSemantic proximity Read ↗

In vivo antiviral efficacy and immune dampening effect of zapnometinib emphasize a dual therapeutic potential against COVID-19Semantic proximity Read ↗

SARS‐CoV‐2 as possible inducer of viral reactivationsSemantic proximity Read ↗

Chronic Viral Reactivation and Associated Host Immune Response and Clinical Outcomes in Acute COVID-19 and Post-Acute Sequelae of COVID-19Semantic proximity Read ↗

JAK inhibitors remove innate immune barriers facilitating viral propagationSemantic proximity Read ↗

Essential contribution of the JAK/STAT pathway to carcinogenesis, lytic infection of herpesviruses and pathogenesis of COVID‑19 (Review)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.